This is not the official budget document.

Budget Summary FY2017

Outside Section 110
Data Current as of:  8/9/2016




Previous Outside Section Next Outside Section

 

First Dose Monitoring

SECTION 110.   Subsection (b) of section 3 of chapter 175H of the General Laws, as appearing in the 2014 Official Edition, is hereby amended by adding the following paragraph:-

(3) This section shall not apply to a discount, rebate or other payment by a pharmaceutical manufacturing company to a patient or another person on the patient's behalf, other than the prescriber of the drug or biologic, for health care items or services related to the patient's use of a drug or biologic of the manufacturer where such items or services are required under a Food and Drug Administration Risk Evaluation and Mitigation Strategy or are for the purpose of monitoring or facilitating the use of the drug or biologic in a manner consistent with the drug or biologic's approved labeling.
 

Veto Explanation:
I am vetoing this section because this effects a broad policy change that should not be made through an outside section in the budget, without the benefit of a public hearing.